We are a clinical-stage biopharmaceutical company

developing novel therapeutics called fatty acid synthase (FASN) inhibitors to treat important diseases such as non-alcoholic steatohepatitis (NASH), acne and various cancers.

Our focus and expertise in fatty acid synthase enables us to break new ground in targeting the dysfunctional metabolic pathways driving these diseases.

body

Our Phase 2 Program in NASH

Our lead product candidate, denifanstat, is an oral, once-daily pill and selective first-in-class FASN inhibitor that is currently being evaluated in an ongoing Phase 2b clinical trial in patients with NASH (FASCINATE-2). Clinical data from a completed Phase 2 clinical trial in patients with NASH (FASCINATE-1) showed that denifanstat was well-tolerated with a favorable pharmacokinetic profile.

Denifanstat Pipeline on Multiple Indications and Clinical Milestones

Stage of Development

Therapeutic area

Indication

Preclinical

Phase 1

Phase 2

Phase 3

TVB-2640

Metabolic disease

TVB-2640
TVB-3567

Dermatology

TVB-2640 (ASC40)*

Oncology

TVB-2640 (ASC40)*

* Trials conducted in China by Ascletis, who has licensed development and commercialization rights to all indications in Greater China

Denifanstat Pipeline on Multiple Indications and Clinical Milestones

Stage of Development

Therapeutic area

Indication

Expected milestone

Preclinical

Phase 1

Phase 2

Phase 3

Metabolic disease

Dermatology

Oncology

** Moderate to advanced fibrosis

** Trials conducted in China by Ascletis, who has licensed development and commercialization rights to all indications in Greater China

Latest Sagimet News